David A. Siegel United Therapeutics Corp Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in United Therapeutics Corp stock. As of the latest transaction made, Two Sigma Advisers, LP holds 113,401 shares of UTHR stock, worth $36.1 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

113,401

Previous 16,601 583.1%

Holding current value

$36.1 Million

Previous $3.65 Million 613.7%

% of portfolio

0.06%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$210.76 - $249.51 $20.4 Million - $24.2 Million	96,800 Added 583.1%	113,401 $26.1 Million
Q4 2023 Feb 14, 2024	BUY	$214.88 - $256.94 $322,320 - $385,410	1,500 Added 9.93%	16,601 $3.65 Million
Q3 2023 Nov 14, 2023	SELL	$211.82 - $248.24 $1.42 Million - $1.66 Million	-6,700 Reduced 30.73%	15,101 $3.41 Million
Q2 2023 Aug 14, 2023	SELL	$205.19 - $232.99 $10.5 Million - $12 Million	-51,400 Reduced 70.22%	21,801 $4.81 Million
Q1 2023 May 15, 2023	SELL	$212.99 - $276.17 $3.98 Million - $5.16 Million	-18,700 Reduced 20.35%	73,201 $16.4 Million

Q4 2022 Feb 14, 2023	BUY	$205.95 - $280.43 $9.64 Million - $13.1 Million	46,800 Added 103.77%	91,901 $25.6 Million
Q3 2022 Nov 14, 2022	BUY	$203.3 - $244.17 $182,970 - $219,753	900 Added 2.04%	45,101 $9.44 Million
Q2 2022 Aug 15, 2022	BUY	$174.81 - $241.14 $4.76 Million - $6.56 Million	27,201 Added 160.01%	44,201 $10.4 Million
Q1 2022 May 16, 2022	SELL	$166.16 - $213.96 $27 Million - $34.8 Million	-162,701 Reduced 90.54%	17,000 $3.05 Million
Q4 2021 Feb 14, 2022	SELL	$184.32 - $216.08 $10.6 Million - $12.4 Million	-57,400 Reduced 24.21%	179,701 $38.8 Million
Q3 2021 Nov 15, 2021	BUY	$179.86 - $214.88 $38.6 Million - $46.1 Million	214,700 Added 958.44%	237,101 $43.8 Million
Q2 2021 Aug 16, 2021	SELL	$170.47 - $211.93 $1.84 Million - $2.29 Million	-10,801 Reduced 32.53%	22,401 $4.02 Million
Q1 2021 May 17, 2021	BUY	$153.94 - $174.85 $5.11 Million - $5.81 Million	33,202 New	33,202 $5.55 Million
Q4 2020 Feb 16, 2021	SELL	$101.87 - $151.79 $24.9 Million - $37.1 Million	-244,602 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$99.9 - $121.13 $13.5 Million - $16.4 Million	-135,001 Reduced 35.56%	244,602 $24.7 Million
Q2 2020 Aug 14, 2020	BUY	$92.74 - $125.82 $139,110 - $188,730	1,500 Added 0.4%	379,603 $45.9 Million
Q1 2020 May 15, 2020	SELL	$79.39 - $115.35 $1.9 Million - $2.76 Million	-23,900 Reduced 5.95%	378,103 $35.9 Million
Q4 2019 Feb 14, 2020	SELL	$78.31 - $95.34 $7.35 Million - $8.95 Million	-93,900 Reduced 18.94%	402,003 $35.4 Million
Q3 2019 Nov 14, 2019	SELL	$74.85 - $85.99 $366,765 - $421,351	-4,900 Reduced 0.98%	495,903 $39.5 Million
Q2 2019 Aug 14, 2019	BUY	$76.06 - $120.81 $33.1 Million - $52.5 Million	434,730 Added 657.95%	500,803 $39.1 Million
Q1 2019 May 15, 2019	SELL	$107.15 - $126.84 $2.15 Million - $2.55 Million	-20,100 Reduced 23.33%	66,073 $7.76 Million
Q4 2018 Feb 14, 2019	SELL	$101.4 - $128.73 $253,500 - $321,825	-2,500 Reduced 2.82%	86,173 $9.38 Million
Q3 2018 Nov 14, 2018	BUY	$113.81 - $129.46 $3.41 Million - $3.88 Million	30,000 Added 51.13%	88,673 $11.3 Million
Q2 2018 Aug 14, 2018	BUY	$101.14 - $118.31 $4.98 Million - $5.82 Million	49,200 Added 519.37%	58,673 $6.64 Million
Q1 2018 May 15, 2018	SELL	$107.21 - $151.94 $943,448 - $1.34 Million	-8,800 Reduced 48.16%	9,473 $1.06 Million
Q4 2017 Feb 14, 2018	BUY	$118.58 - $151.28 $1.83 Million - $2.33 Million	15,402 Added 536.47%	18,273 $2.7 Million
Q3 2017 Nov 14, 2017	BUY	$114.6 - $136.81 $329,016 - $392,781	2,871	2,871 $336,000

Others Institutions Holding UTHR

# of Institutions

561

Shares Held

43.1M

Call Options Held

501K

Put Options Held

529K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $14.5B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account